A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC

NCT07264816 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

80

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-squamous Non-small Cell Lung Cancer

Interventions

DRUG: BL-M07D1
DRUG: Pembrolizumab

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.